ESR1 Mutation Emergence and the SERENA-6 Treatment Strategy in First-Line Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

The faculty open the episode by discussing how most patients with hormone receptor-positive, HER2-negative metastatic breast cancer begin treatment with a CDK4/6 inhibitor plus an aromatase inhibitor and many respond well, sometimes for years.

Neil Iyengar, MD; Rebecca Shatsky, MD; and Carol Tweed, MD, discuss camizestrant and SERENA-6 ctDNA monitoring for ESR1-mutant HR+/HER2– breast cancer.